CT 101 / Sienna - LARVOL DELTA

"@PCRonline @mirvatalasnag @sbrugaletta @Ortega_Paz @NicolaRyanI1 @CCook_MD @TomJFord @nickaram @KambisMashayek1 @chipkaminsky @aspergian1 @perc_surgeon @lewis052 @ziadalinyc @lorenzo2509 @Dr_Bitar @agtruesdell @OptimaCTO @LATAMCTO #EPeeps #CTO101 #EAPCI" (@jedicath)

"Comments pls..🤣 I’ll start: #CTO101 @DocSavageTJU @SanChris999 @skilicmd @mmamas1973 @RhianEDavies1 @rational_doc @aspergian1 @SJcardio @Pooh_Velagapudi @Tabaza @HadyLichaaMD @KTamirisaMD @skarim01 @Almanfi_Cardio @SGuptaMD @lorenzo2509 @phillipfreeman @colum_owens" (@mirvatalasnag)

"Would you switch to retrograde for this near flush occluded RCA #CTO101 if needed? No septals. Large tortuous LAD epicardial. If so, microcatheter of choice? @evandrofilhobr @perc_surgeon @DrAmirKaki @Babar_Basir @KAlaswadMD @Retrograde_CTO" (@yasirakhtarMD)

"#cardiotwitter #tavi #TAVR #cto #cto101 @dr_benoy_n_shah @Stephenhenrydo1 @bartstructural @Ryvetsprog @DavidLBrownMD @nolanjimradial @adamtsao13" (@phillipfreeman)

"How to remove a microcatheter https://t.co/0NlFDKK2o0 via @esbrilakis 5th is a 300 cm guidewire #CTO101. #cardiotwitter" (@jedicath)

EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) (clinicaltrials.gov) - P1; N=6; Not yet recruiting; Sponsor: Invectys

Clinical • New P1 trial • Oncology • Solid Tumor

"How about #PCI101 similar to #CTO101? What do you think @rwyeh? https://t.co/aXO64iK5Mh" (@willsuh76)

"Sounds great @rwyeh #IC join in? @Ravinay are you aware of @rwyeh proposed #CTO101 educational t" (@AnastasiaSMihai)

Biosimilar • Women's Health

"#CTO101" (@DrSheilaSahni)

Biosimilar

"FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant https://t.co/UMG38No9uJ" (@NewsFromBW)

Evaluation of the Class I histone deacetylase (HDAC) inhibitor CT-101 on fetal hemoglobin (HbF) expression in sickle progenitors and transgenic mice (FSCDR 2020) - No abstract available

"#CopyLeft #UpsideDownLove #CTO101 Not my image" (@mirvatalasnag)

"@MLCTOcourse @cto101 @esbrilakis @GreggWStone @SripalBangalore @KambisMashayek1" (@AlesqQuadros)

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=15; Recruiting; Sponsor: Kai Lin Xu; Jun Nian Zheng

New P1 trial

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1; N=9; Not yet recruiting; Sponsor: The First Affiliated Hospital with Nanjing Medical University; Initiation date: Aug 2019 ➔ Dec 2019

Clinical • Trial initiation date

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1; N=9; Not yet recruiting; Sponsor: The First Affiliated Hospital with Nanjing Medical University

Clinical • New P1 trial